MARSHALL WACE, LLP - PROGENICS PHARMACEUTICALS IN ownership

PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 100 filers reported holding PROGENICS PHARMACEUTICALS IN in Q4 2014. The put-call ratio across all filers is 0.25 and the average weighting 0.1%.

Quarter-by-quarter ownership
MARSHALL WACE, LLP ownership history of PROGENICS PHARMACEUTICALS IN
ValueSharesWeighting
Q4 2018$58,000
-62.1%
13,985
-32.0%
0.00%
-50.0%
Q2 2015$153,000
+24.4%
20,5670.0%0.00%0.0%
Q1 2015$123,000
-20.6%
20,5670.0%0.00%0.0%
Q4 2014$155,000
-82.3%
20,567
-87.8%
0.00%
-84.6%
Q3 2014$875,000168,6570.01%
Other shareholders
PROGENICS PHARMACEUTICALS IN shareholders Q4 2014
NameSharesValueWeighting ↓
ARDSLEY ADVISORY PARTNERS LP 1,255,000$5,823,0001.12%
Phocas Financial Corp. 1,146,292$5,319,0000.54%
Worth Venture Partners, LLC 138,357$641,0000.36%
RICE HALL JAMES & ASSOCIATES, LLC 2,293,179$10,640,0000.34%
Monashee Investment Management LLC 240,000$1,114,0000.26%
BKS ADVISORS, LLC 118,587$550,0000.22%
PINNACLE ASSOCIATES LTD 1,418,391$6,581,0000.15%
FARALLON CAPITAL MANAGEMENT LLC 4,200,820$19,492,0000.15%
Fosun International Ltd 472,580$2,174,0000.14%
CARILLON TOWER ADVISERS, INC. 3,948,024$18,318,0000.13%
View complete list of PROGENICS PHARMACEUTICALS IN shareholders